Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
Last trade$13.53
Day change-$0.28 (-2.03%)
Day range$13.33 – $14.40
Volume37,168
Market cap$157M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$156.54M
Price / earnings
31.8×
Price / book
3.05×
Price / sales
0.6×
EV / sales
0.55×
EV / EBITDA
6.72×
Profitability
Earnings per share
$0.43
Return on assets
2.26%
Return on equity
9.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.75×
Quick ratio
0.71×
Cash ratio
0.09×
Cash flow
Price / cash flow
7.25×
Price / free cash flow
9.66×
Free cash flow
$16.21M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FC, quarterly periods
Line item
Q4 FY2026 Aug 31, 2026
Q3 FY2026 May 31, 2026
Q2 FY2026 Feb 28, 2026
Q1 FY2026 Nov 30, 2025
Q4 FY2025 Aug 31, 2025
Q3 FY2025 May 31, 2025
Q2 FY2025 Feb 28, 2025
Q1 FY2025 Nov 30, 2024
Revenue
$69.96M
$67.81M
$59.65M
$64.05M
$71.25M
$67.12M
$59.61M
$69.09M
Cost of revenue
$17.67M
$17.71M
$14.37M
$15.67M
$17.46M
$15.8M
$13.87M
$16.38M
Gross profit
$52.29M
$50.1M
$45.27M
$48.37M
$53.79M
$51.32M
$45.75M
$52.71M
Selling, general and administrative
$40.49M
$43.26M
$43.5M
$46.12M
$42.15M
$46.23M
$45.09M
$47.2M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$43.45M
$45.9M
$47.27M
$52.03M
$45.9M
$53.53M
$47.2M
$51.24M
Operating income
$8.84M
$4.2M
-$2M
-$3.65M
$7.89M
-$2.2M
-$1.46M
$1.48M
Interest expense
-$69K
-$54K
-$92K
-$95K
-$95K
-$135K
-$156K
-$178K
Income before taxes
$8.59M
$4.17M
-$2.06M
-$3.63M
$7.96M
-$2.13M
-$1.35M
$1.59M
Income taxes
$1.48M
$1.08M
-$80K
-$343K
$3.58M
-$718K
-$272K
$406K
Net income
$7.11M
$3.09M
-$1.98M
-$3.29M
$4.37M
-$1.41M
-$1.08M
$1.18M
Net income attributable to common shareholders
$7.11M
$3.09M
-$1.98M
-$3.29M
$4.37M
-$1.41M
-$1.08M
$1.18M
EBITDA
$11.71M
$6.69M
$1.32M
$1.58M
$10.07M
$4.65M
$660K
$5.51M
Basic earnings per share
$0.63
$0.27
-$0.17
-$0.27
$0.35
-$0.11
-$0.08
$0.09
Diluted earnings per share
$0.60
$0.27
-$0.17
-$0.27
$0.34
-$0.11
-$0.08
$0.09
Recent news
Company coverage with links to the original publishers.
Franklin Covey reported Q3 2026 earnings of $0.62 per share, beating the consensus estimate of $0.59, but revenues of $69.96 million missed expectations by 3.16%. The company has underperformed the S&P 500 year-to-date, gaining 2.3% versus the market's 10.6%. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Consulting Services industry ranks in the top 25% of Zacks industries.
Huron Consulting reported Q3 2026 earnings of $2.62 per share, beating consensus estimates of $2.47 and representing a 6.07% surprise. Revenue of $482.52 million also exceeded expectations by 0.50%. The company has outperformed the S&P 500 by 2.6% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revision trends, suggesting near-term performance in line with the market.
FTI Consulting reported quarterly earnings of $3.84 per share, significantly beating the consensus estimate of $2.65 and representing a 44.91% earnings surprise. Revenue also exceeded expectations at $1.01 billion. However, the stock has underperformed the market year-to-date, declining 7.2% versus the S&P 500's 13.1% gain. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Pomerantz LLP announced investigations into potential securities fraud at AstraZeneca following the failure of its Phase-3 CARDIO-Transform trial for Wainua treatment, which caused the stock to drop 5.7%. The firm is also investigating claims against Alibaba Group and Franklin Covey Co.
Pomerantz LLP is investigating potential securities fraud claims against Franklin Covey Co. following the company's July 1, 2026 earnings report that missed revenue estimates ($67.81M vs. $68.33M consensus) and significantly lowered full-year guidance to $260-267M from $265-275M. The disappointing results, attributed to geopolitical tensions and execution risks, triggered a 12.85% stock price decline on July 2, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.